Loading...
Login/Register
Welcome
Profile
Log Off
text
title
chapter title
keyword
WHO Home
WHO Health Systems and Services
WHO Medicines
WHO sites
Medicines Documentation home
Search
Titles A-Z
Subjects
Keywords
Series and Periodicals
Publishers
Authors A-Z
Regions
Countries
Index
Sub-collections
Public
sub-collections
Expand Document
|
Expand Chapter
|
Full TOC
|
Printable HTML version
::
Themes & Keywords
·
Keywords
>
pharmaceuticals newsletter
WHO Pharmaceuticals Newsletter 1999, No. 07&08
(1999; 18 pages)
Table of Contents
Regulatory actions
Albumin (human): review of safety: conclusions: UK
Astemizole: voluntary withdrawal: Janssen, USA
Cisapride: revised labelling: QT syndrome and drug interactions: USA
Follitropin alfa: batch withdrawn: stability problems: EU
Hetastarch (hydroxyethylstarch): fatal haemorrhages: France
Minocycline: immunoallergic and liver damage with long-term therapy: Germany
Oral contraceptives containing gestodene or desogestrel: update: revised product information: UK
Pemoline: revised labelling: liver function monitoring: Abbott, USA
Phenol: warning concerning topical solutions: New Zealand
Progestational drug products: requirements for patient labelling: proposed rule: USA
Substandard medicines: distribution and prescription prohibited: Venezuela
Sunscreen products: requirements: final rule: USA
Tranylcypromine/trifluoperazine: licence not renewed: UK
Troglitazone: restricted indications: USA
Trovafloxacin and alatrofloxacin: suspended: Spain
Drug surveillance
Antidepressants and falls in the elderly: association: Spain
Drug-induced aplastic anaemia: chloramphenicol eyedrops and nifedipine: Spain
Herbal medicines regulation: call for public debate: UK
New developments
Rofecoxib: approved for osteoarthritis and pain: USA
Rosiglitazone: approved for adult-onset diabetes: USA
New indications
New formulations
Newly approved products
Medical devices
Glucose monitoring system: new device approved: USA
Masculine condoms (Romed): withdrawn from the market: Portugal
Radiopharmaceuticals (in vivo): regulations for diagnosis and monitoring: final rule: USA
Medication errors
Chlorpromazine and chlorpropamide: name confusion: USA
Coloured oral syringes: potential for errors: USA
Dosage confusion: importance of double checking highlighted: USA
Ketamine (Ketalar): concentration confusion: USA
General information
Fibrin sealant products: guidance available: USA
International Nonproprietary Names (INNs): exemption from customs duty: Germany
WHO Pharmaceuticals Newsletter 1999, No. 07&08
Essential Drugs and Medicines Policy
WHO.INT
World Health Organization
Contacts
|
E-mail scams
|
Employment
|
FAQs
|
Feedback
|
Privacy
|
RSS feeds
© WHO 2013
Last updated: May 3, 2013